TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
|Slideshows|August 28, 2018
Diabetes News Roundup: August 2018
Author(s)Mark L. Fuerst
Highlights include obstructive sleep apnea as a factor for T2DM; a test that distinguishes between T1DM and T2DM; and missed opportunities in diabetes prevention.
Advertisement
Advertisement
Related to this article
Tom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.
Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.
Compared to metformin, GLP-1 RAs were linked to more normoglycemia reversion and less diabetes progression in 256,492 adults with prediabetes.
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
2
Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control
3
Enlicitide Lowers LDL-C Consistently Across PREVENT CVD Risk Categories
4
Diabetes Dialogue: Retatrutide Tops Semaglutide on A1C, Weight in T2D
5